Official ESCRS | European Society of Cataract & Refractive Surgeons
Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount
title

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

The association between rs1800625 polymorphism and exudative age-related macular degeneration development

Poster Details


First Author: M. Banevicius LITHUANIA

Co Author(s): A. Vilkeviciute   L. Kriauciuniene   R. Liutkeviciene              

Abstract Details

Purpose:

Age-related macular degeneration (AMD) is the leading cause of blindness in people age 65 and older in developed countries. Age, gender, genetic factors and others havealready been identifiedas rik factors for amd development. The AGEs are involved in the pathogenesis of AMD through the AGE and receptor for AGE (RAGE) interaction, which can be altered by polymorphism in RAGE gene. In our study, we examined one single nucleotide polymorphism (SNP) in AGER gene (rs1800625), a coding variant in the AGER gene which may be a risk factor for exudative AMD development.

Setting:

Department of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy Neuroscience Institute, Lithuanian University of Health Sciences, Medical Academy

Methods:

The study enrolled n = 171 patients with exudative AMD and a random sample of the healthy control group n = 263. The genotyping was carried out using the real-time polymerase chain reaction (RT-PCR) method.

Results:

The analysis of rs1800625 gene polymorphism did not reveal any differences in the distribution of A/A, A/G, and G/G genotypes between the exudative AMD and control groups (60.2%, 32.7%, and 7.0% vs. 66.5%, 24.3% and 9.1%, respectively), p=0.146).

Conclusions:

Our study did not reveal any significant associations between rs1800625 polymorphism in RAGE gne and the risk of exudative AMD development.

Financial Disclosure:

None

Back to Poster listing